Patient persistence with first-line antiglaucomatous monotherapy

Alfonso Arias1, Konrad Schargel2, Fernando Ussa3, Maria I Canut4, Amelia y Bel&eacute;n Robles4, Bel&eacute;n Mart&iacute; S&aacute;nchez51Ophthalmology Department, Fundaci&oacute;n Hospital Alcorc&oacute;n, Madrid; 2Ophthalmology Department, Hospital...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alfonso Arias, Konrad Schargel, Fernando Ussa, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ac707c60abd644539e59ff9516e4938d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac707c60abd644539e59ff9516e4938d
record_format	dspace
spelling	oai:doaj.org-article:ac707c60abd644539e59ff9516e4938d2021-12-02T08:06:33ZPatient persistence with first-line antiglaucomatous monotherapy1177-54671177-5483https://doaj.org/article/ac707c60abd644539e59ff9516e4938d2010-04-01T00:00:00Zhttp://www.dovepress.com/patient-persistence-with-first-line-antiglaucomatous-monotherapy-a4220https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Alfonso Arias1, Konrad Schargel2, Fernando Ussa3, Maria I Canut4, Amelia y Bel&eacute;n Robles4, Bel&eacute;n Mart&iacute; S&aacute;nchez51Ophthalmology Department, Fundaci&oacute;n Hospital Alcorc&oacute;n, Madrid; 2Ophthalmology Department, Hospital de Torrevieja, Alicante; 3Instituto Universitario de Oftalmobiolog&iacute;a Aplicada, Valladolid; 4Centro de Oftalmolog&iacute;a Barraquer, Barcelona; 5Aut&oacute;noma University of Madrid, Madrid, SpainPurpose: To identify the extent of persistence (period of time of continuous therapy with the drug prescribed) of glaucoma patients treated with prostaglandins (latanoprost, bimatoprost, or travoprost), or &beta;-blocker (timolol) monotherapy.Methods: An observational retrospective study of a 24-month follow-up in 191 patients (from four centers) was done to identify the time elapsed until patients discontinued their antiglaucomatous treatment. The relevant information was extracted from patients&rsquo; medical charts. A descriptive analysis, a Kaplan&ndash;Meier survival analysis, and a Cox regression model were used to determine which drug was associated with greater patient persistence and to detect variables significantly influencing persistence.Results: Descriptive analysis and survival curves showed that after 24 months, latanoprost was associated with a higher persistence in glaucoma treatment than the alternative agents: 81.6% versus 22.9% for bimatoprost, 65.4% for travoprost, and 60.5% for timolol (P &lt; 0.0001). Persistence was significantly influenced by the antiglaucoma agent used as monotherapy (with a six-fold higher risk of treatment discontinuation during the follow-up period due to receiving bimatoprost instead of latanoprost; P &lt; 0.0001) and patient age (P = 0.001). Even though comorbidities could not be directly related to persistence, their occurrence was related to patient age. The main reasons for treatment discontinuation were lack of efficacy, development of intolerance and/or adverse events, which were significant in the bimatoprost group, 28.6% (P &lt; 0.001) and 48.6% (P &lt; 0.001), respectively.Conclusions: Latanoprost shows higher patient persistence compared with travoprost, bimatoprost, and timolol in routine clinical practice, and could lead to better control of intraocular pressure and lower associated economic costs.Keywords: first-line monotherapy, glaucoma, treatment, persistence, Spain Alfonso AriasKonrad SchargelFernando Ussaet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 261-267 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Alfonso Arias Konrad Schargel Fernando Ussa et al Patient persistence with first-line antiglaucomatous monotherapy
description	Alfonso Arias1, Konrad Schargel2, Fernando Ussa3, Maria I Canut4, Amelia y Bel&eacute;n Robles4, Bel&eacute;n Mart&iacute; S&aacute;nchez51Ophthalmology Department, Fundaci&oacute;n Hospital Alcorc&oacute;n, Madrid; 2Ophthalmology Department, Hospital de Torrevieja, Alicante; 3Instituto Universitario de Oftalmobiolog&iacute;a Aplicada, Valladolid; 4Centro de Oftalmolog&iacute;a Barraquer, Barcelona; 5Aut&oacute;noma University of Madrid, Madrid, SpainPurpose: To identify the extent of persistence (period of time of continuous therapy with the drug prescribed) of glaucoma patients treated with prostaglandins (latanoprost, bimatoprost, or travoprost), or &beta;-blocker (timolol) monotherapy.Methods: An observational retrospective study of a 24-month follow-up in 191 patients (from four centers) was done to identify the time elapsed until patients discontinued their antiglaucomatous treatment. The relevant information was extracted from patients&rsquo; medical charts. A descriptive analysis, a Kaplan&ndash;Meier survival analysis, and a Cox regression model were used to determine which drug was associated with greater patient persistence and to detect variables significantly influencing persistence.Results: Descriptive analysis and survival curves showed that after 24 months, latanoprost was associated with a higher persistence in glaucoma treatment than the alternative agents: 81.6% versus 22.9% for bimatoprost, 65.4% for travoprost, and 60.5% for timolol (P &lt; 0.0001). Persistence was significantly influenced by the antiglaucoma agent used as monotherapy (with a six-fold higher risk of treatment discontinuation during the follow-up period due to receiving bimatoprost instead of latanoprost; P &lt; 0.0001) and patient age (P = 0.001). Even though comorbidities could not be directly related to persistence, their occurrence was related to patient age. The main reasons for treatment discontinuation were lack of efficacy, development of intolerance and/or adverse events, which were significant in the bimatoprost group, 28.6% (P &lt; 0.001) and 48.6% (P &lt; 0.001), respectively.Conclusions: Latanoprost shows higher patient persistence compared with travoprost, bimatoprost, and timolol in routine clinical practice, and could lead to better control of intraocular pressure and lower associated economic costs.Keywords: first-line monotherapy, glaucoma, treatment, persistence, Spain
format	article
author	Alfonso Arias Konrad Schargel Fernando Ussa et al
author_facet	Alfonso Arias Konrad Schargel Fernando Ussa et al
author_sort	Alfonso Arias
title	Patient persistence with first-line antiglaucomatous monotherapy
title_short	Patient persistence with first-line antiglaucomatous monotherapy
title_full	Patient persistence with first-line antiglaucomatous monotherapy
title_fullStr	Patient persistence with first-line antiglaucomatous monotherapy
title_full_unstemmed	Patient persistence with first-line antiglaucomatous monotherapy
title_sort	patient persistence with first-line antiglaucomatous monotherapy
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/ac707c60abd644539e59ff9516e4938d
work_keys_str_mv	AT alfonsoarias patientpersistencewithfirstlineantiglaucomatousmonotherapy AT konradschargel patientpersistencewithfirstlineantiglaucomatousmonotherapy AT fernandoussa patientpersistencewithfirstlineantiglaucomatousmonotherapy AT etal patientpersistencewithfirstlineantiglaucomatousmonotherapy
_version_	1718398679028596736

Patient persistence with first-line antiglaucomatous monotherapy

Ejemplares similares